Summary
Introduction
its actions is not known. The CNS is generally shielded from the circulation by the blood-brain and blood-spinal cord barriers. Some GM-CSF can be produced within the CNS when glia are stimulated by immune challenge (Giulian et al., 1994) , and it is thought that the higher concentrations of GM-CSF seen in brain tissue during some infections represent secretions of invading macrophages (Achim et al., 1993 ). An additional means of possible CNS access, which has not been previously investigated, is that GM-CSF is capable of crossing the blood-brain barrier. This last possibility is particularly intriguing since it would not necessarily require a precipitating event to provide GM-CSF access to the CNS. We therefore designed a study to determine whether GM-CSF crossed the blood-brain and blood-spinal cord barriers.
Material and methods

Radioactive labelling
Murine, recombinant, carrier-free GM-CSF (R & D Systems, Minneapolis, Minn., USA) was labelled with 125 I by the enzymobead method (Biorad, Richmond, Calif., USA) and purified on columns of Sephadex G-50. The specific activity of the purified product was~4.0ϫ10 7 c.p.m./µg. About 92% of 125 I counts from G-50 purified GM-CSF could be precipitated with acid. Purified GM-CSF appeared as a single band of correct molecular weight when visualized on an acrylamide gel. Albumin was labelled with 99m Tc with a kit from MediϩPhysics (Paramus, NJ, USA). About 95% of 99m Tc albumin radioactivity could be precipitated with acid.
Measurement of passage of GM-CSF from blood to brain and spinal cord
Animals were treated according to procedures which conform to American Association for Accreditation of Laboratory Animal Care standards, and which were approved by our institutional animal care committee.
Male and female, ICR mice (23-25 g) and male SpragueDawley rats (250-320 g), both from Charles River (Wilmington, Mass., USA), were anaesthetized with 7.5 µl/ g 40% urethane, or 60 mg/kg pentobarbital. The left jugular vein was exposed and the right carotid artery isolated. Animals received injections into the left jugular vein of 0.2-ml lactated Ringer's solution with 1% bovine serum albumin, 5 ϫ 10 6 c.p.m. of [ 125 I]GM-CSF, and 5 ϫ 10 6 c.p.m. of 99m Tc-albumin. Animals were decapitated at specific time points between 1 and 60 min after the injection. Blood was collected from the right carotid artery immediately before decapitation. Brains and spinal cords were removed, weighed, and counted for 125 I and 99m Tc. Blood was centrifuged for 10 min at 4500 g at 4°C, and 0.05 ml of serum was removed and counted. Serum samples also were precipitated with trifluoroacetic acid as a measure of the degradation of GM-CSF in blood.
Blood-to-brain and blood-to-spinal cord transport rates were determined by multiple-time regression analysis (Patlak and Fenstermacher, 1975) . This method allows for a unidirectional influx constant (K i ) across a biological barrier to be calculated after an in vivo injection of the substance. The amount of label in spinal cord or brain is expressed as a ratio of counts per minute (c.p.m./g of whole tissue)/ (c.p.m./ml of serum) to give units of ml/g. Increases in the ml/g ratio with time generally indicate that the substance is crossing the barrier. Since concentrations of most proteins will not remain constant in serum after in vivo injection, the rate of passage across the barrier (as given by the K i ) is calculated with exposure time rather than standard (or clock) time. Exposure time has the same units (min) as clock time, but is extended to compensate for the fact that serum concentrations of an injected protein are not constant across time.
The unidirectional influx constants (K i ), expressed in ml/ g-min, were determined from the linear portion of the curve by the two equations.
where A m is the level of radioactivity in brain or spinal cord at time t, V i is the apparent volume of distribution in brain or spinal cord, C p is the c.p.m./ml of arterial serum and t is time. Exposure times were calculated separately for each group of animals used and for each day during which an experiment was performed. After initial comparisons between entry rates for GM-CSF and albumin, ratios of albumin were subtracted from ratios of GM-CSF as a correction for leakage of blood and for non-specific passage across the blood-brain barrier. Except where indicated, experimental animals were male.
Comparison of blood-brain barrier passage in male and female animals
To compare blood-brain barrier passage of GM-CSF between the sexes, a measurement of entry rate was performed with groups of eight mice of each sex. Both groups of animals were injected on the same day, by the same experimenter, and care was taken to randomize any factors that were necessarily different between groups, such as which animal received the first injection at each time point. As in all the experiments measuring rate of entry, the K i s between the two groups were compared after correction for leakage by subtraction of 99m Tc-albumin counts.
Saturation
To determine whether GM-CSF was entering the brain by a saturable system, an additional entry rate measurement was performed with two groups of mice. The entry rate for GM-CSF for each group was determined as described above, with the exception that one group of mice received 150 µg/kg unlabelled GM-CSF along with the injection of labelled compound. The same controls performed for other group comparison studies were used.
Inhibition of the large neutral amino acid transporter with L-tryptophan To help ensure that the entry rate measured was in fact an indication of GM-CSF transport, and not of radioactive amino acid break-down products, an entry rate measurement was performed with two groups of mice. The entry rate for GM-CSF for each group was determined as described above, with the exception that one group of mice received 10 mg/kg unlabelled L-tryptophan along with the injection of labelled GM-CSF. Both [ 125 I]tyrosine and L-tryptophan enter the brain by the large neutral amino acid transport system, and each inhibits the other's entry. L-Tryptophan, rather than tyrosine, was used here because its greater water solubility allows a higher concentration of amino acid to be injected. The same controls performed for other group comparison studies were used. The K i s between the two groups were compared, correcting for leakage.
High performance liquid chromatography (HPLC)
The degree to which GM-CSF was degraded in brain and serum was determined by HPLC analysis of samples taken from mice 5, 10 and 15 min after injection. Samples were homogenized in lactated Ringer's solution with an ultrasonic cell disrupter, centrifuged for 1 min at 2000 g and the supernatants lyophilized. To correct for degradation due to tissue processing, control values (time ϭ 0) were obtained by direct addition of radioactivity to blood or brain before processing. Samples were reconstituted in 0.1% trifluoroacetic acid, and twice centrifuged for 10 min at 4000 g. Supernatants were analysed by reversed-phase HPLC with a C4 protein column and a 1 ml/min solvent flow rate. The solvent gradient was increased from 30 to 90% acetonitrile in a linear fashion over the course of 30 min and was maintained at a constant concentration of 0.1% trifluoroacetic acid. Results for serum and brain are reported after correction for degradation during processing.
Capillary depletion
Mice were injected with radio-labelled GM-CSF and albumin as described above. Cortex, which does not contain any circumventricular organs, was gently homogenized in 0.8 ml cold capillary depletion buffer (10 mM HEPES, 141 mM NaCl, 4 mM KCl, 2.8 mM CaCl 2 , 1 mM MgSO 4 , 1 mM NaH 2 PO 4 and 10 mM D-glucose; pH 7.4) with a hand homogenizer. Then, 1.7 ml of 26% dextran was added, the mixture vortexed thoroughly, and centrifuged for 10 min at 5400 g in a swinging bucket ultracentrifuge. Supernatants, which consist of the brain parenchyma and interstitial fluids, and pellets, which consist of the brain capillary enriched fraction, were separated and counted for radioactivity. Parenchymal fractions were corrected for vascular contamination as measured by 99m Tc-albumin counts.
To test for GM-CSF that might be loosely adherent to capillaries, this process was repeated with the exception that brains were washed by perfusion of the animal with lactated Ringer's immediately before decapitation. For perfusion, the heart was exposed and blood was taken from the vena cava. The thoracic aorta was clamped, and jugular veins severed. Mice were perfused through the left ventricle of the heart with 20 ml of lactated Ringer's before decapitation.
Statistics
Regression lines were computed by the least squares method where the relationship between A m /C p( t) and exposure time was linear. Outliers were removed, regression lines plotted with Cricket Graph software (Malvern, Pa., USA), and slopes compared by GraphPad Prism software (San Diego, Calif., USA). The K i s are given with standard deviation of the residuals (Sy.x).
Results
GM-CSF crossed the blood-brain barrier. A significant relation was observed between brain : blood ratios for GM-CSF and exposure time, and the passage rate for GM-CSF significantly exceeded that of albumin (Figs 1 and 2 ). With brain : blood ratios for GM-CSF corrected for vascular space and leakage (as measured by albumin), GM-CSF passage across the mouse blood-brain barrier showed a K i of 2.9ϫ10 -4 Ϯ 0.002 ml/g-min, meaning that an amount of GM-CSF found in 2.9 ϫ 10 -4 Ϯ 0.002 ml of blood entered a gram of brain each minute of exposure time. If not corrected for albumin leakage, the K i would be 4.04 ϫ 10 -4 Ϯ 0.004 and the V i would be 9.7 ϫ 10 -3 . Some variability was seen in the half-time disappearance of GM-CSF from blood in experiments performed with [ 125 I]GM-CSF labelled on different days, but compensating for this with the calculation of exposure time, rates of passage were fairly consistent between experiments.
GM-CSF crossed the blood-brain barrier in both male and female mice. Data from female animals exhibited more variability than did data from males, but no significant difference was observed between the passage rates across the blood-brain barrier in males and females (Fig. 3) . GM-CSF also crossed the blood-brain barrier in rats (Fig. 2) . The K i in rat was 7.91 ϫ 10 -4 Ϯ 0.002, after correction for albumin.
Significant passage of GM-CSF was also observed across the murine blood-spinal cord barrier (Fig. 4) . As in brain, a significant relationship was observed between brain : blood ratios for GM-CSF and exposure time. Likewise, GM-CSF uptake by spinal cord exceeded that of albumin. The K i for passage across the blood-spinal cord barrier was 1.99 ϫ 10 -4 Ϯ 0.0007, after correction for leakage.
In order to verify that the radioactivity crossing the bloodbrain barrier was intact [ 125 I]GM-CSF, and not break-down products, a number of controls were performed. Since bloodbrain barrier passage of [ 125 I]tyrosine might result in artifactual results, we inhibited the large neutral amino acid transporter by co-injecting a saturating concentration of unlabelled tryptophan along with the [ 125 I]GM-CSF. This coinjection, however, had no significant effect on transport of the radioactive material (Fig. 5) .
To test for integrity of the label in the form of GM- CSF, radioactivity from samples of serum and brain were precipitated with trifluoroacetic acid (Fig. 6) . Precipitation of 125 I counts showed a slow decline in both brain and serum over the course of time. The relation was significant (P Ͻ 0.001) versus exposure time, with~1% reduction in precipitability each min.
With the V i and K i in addition to the precipitation data, it was possible to calculate what percentage of the counts inside the blood-brain barrier could be precipitated. For example, at an exposure time of 24 min, the V i is~50% of the total counts in the brain, 64% of the counts from whole brain precipitated, and 68% of the counts of serum precipitated. Fig. 3 Comparison of blood to brain passage of GM-CSF in male and female mice. Both males and females showed significant passage of GM-CSF into the brain (P Ͻ 0.005). Overall rates of passage were not significantly different between males and females. Data from female animals showed greater variability than that from their male counterparts, however (r ϭ 0.965 in males, r ϭ 0.835 in females).
Any counts above V i represent radioactivity that has crossed the blood-brain barrier, so~50% of the counts are inside the blood-brain barrier at this time. Radioactivity detected in whole brain is made up of counts outside the blood-brain barrier (mostly from blood found within the vasculature of the brain) and counts inside the blood-brain barrier (those greater than V i ). With the conservative estimate that precipitation outside the blood-brain barrier can be represented by serum, the following equation can be used to solve for the precipitibility of radioactivity inside the bloodbrain barrier: Whole brain precipitation ϭ [(fraction outside the bloodbrain barrier) (serum precipitation)] ϩ [(fraction inside the blood-brain barrier) (precipitation inside the blood-brain barrier)]
Since whole brain precipitation, serum precipitation, the fraction inside the blood-brain barrier and the fraction outside the blood-brain barrier are all known, it can be calculated that 60% of the counts inside the blood-brain barrier were acid-precipitable at an exposure time of 24 min. Similar calculations show that precipitable GM-CSF can be found within the blood-brain barrier at all time points measured (Table 1) .
Since large fragments of GM-CSF might also be precipitated with acid, HPLC was performed to identify the intact protein. Significant degradation was found to occur in brain and serum (Table 2) , but nevertheless intact GM-CSF was recovered from brain at all three measured time points at higher concentrations than would be predicted by the presence of intact label in the brain vasculature (Table 1) .
Capillary depletion (Fig. 7) was performed to determine whether GM-CSF was capable of penetrating into the brain parenchyma, or whether the cytokine was taken up by the capillary endothelium. Only 6.9 Ϯ 1.3% of counts were found in the capillary-enriched fraction after differential centrifugation, a percentage that was not significantly altered by the washing of the brain by perfusion with lactated Ringer's solution.
Since intact GM-CSF was found to enter the brain parenchyma, an experiment was performed to determine whether this passage occurred by means of a saturable system. unlabelled GM-CSF, showed significant inhibition of bloodbrain barrier and blood-spinal cord barrier passage by the unlabelled compound (Fig. 8) , indicating that GM-CSF crosses from blood to CNS by means of a saturable system.
Discussion
The major finding of this study is that GM-CSF crosses the blood-brain and blood-spinal cord barriers. Passage of GM-CSF across the blood-brain barrier was found to occur in both mice and rats, and in both males and females. This is the first evidence that a colony-stimulating factor, a family Fig. 7 Passage of GM-CSF into capillaries, brain parenchyma and whole brain. Only 6.9 Ϯ 1.3 % was found in the capillary fraction. No significant effect of washout was seen on the percentage of counts found in capillaries. that includes GM-CSF, granulocyte colony-stimulating factor and macrophage colony-stimulating factor, crosses directly from blood into the CNS. That GM-CSF, labelled with 125 I on its tyrosine residues, was crossing the blood-brain barrier as an intact protein was confirmed by three methods. Passage of free [ 125 I]tyrosine was ruled out by saturation of the large neutral amino acid transporter with L-tryptophan. L-Tryptophan is carried across the blood-brain barrier by the same transporter as L-tyrosine, but, because it is more soluble, larger concentrations can be administered to saturate the system.
Table 1 Minimum percentage of GM-CSF counts inside the blood-brain barrier that is intact
The possibility that the counts in brain might be free 125 I or small peptide fragments was eliminated by precipitation of brain and serum samples with trifluoroacetic acid. Using this method, we demonstrated that a significant portion of the precipitating, and therefore protein-bound, radioactivity in the brain could not be accounted for by vascular contamination.
The presence of GM-CSF in brain was confirmed finally by HPLC to detect the full protein. Once again, vasculature content could not account for all the intact GM-CSF detected. For the results of studies by both precipitation and HPLC, the values presented should be considered as the minimum amounts of intact GM-CSF that crossed the blood-brain barrier, since a significant amount of the degradation or alteration of GM-CSF may have taken place inside the brain after crossing the blood-brain barrier.
A larger amount of radioactivity in brain was acid precipitable than was identified by HPLC as intact GM-CSF. At least two possibilities could explain this discrepancy. GM-CSF could have been cleaved into large protein fragments, which would still be precipitated with acid, but which would not show up as intact protein by HPLC. If such fragments did exist, it is possible that they could maintain the necessary regions to interact with the GM-CSF receptor, the putative transporter, or both. An alternate explanation for the discrepancy between the results with HPLC and precipitation is that GM-CSF was glycosylated in vivo. Glycosylation can dramatically change the molecular weight of GM-CSF, although the different forms of the protein all maintain bioactivity (Hill et al., 1995) . It is possible that glycosylation occurred within the brain, and that such altered forms of the protein were no longer eluted from the HPLC column at the same place as the original labelled compound. If this were true, the full amount of precipitating counts would probably represent bioactive GM-CSF. In either case, however, results by both HPLC and precipitation clearly indicate that a substantial percentage of GM-CSF crossed the blood-brain barrier in the intact form.
Capillary depletion revealed that the majority of the GM-CSF penetrated the brain parenchyma rather than sticking to the capillaries. By addition of the further step of perfusing the brain before capillary depletion, we were able to divide the capillary fraction further, to avoid contamination from blood-borne counts and to determine whether a portion of the GM-CSF was loosely adherent to the capillaries. For some proteins this ability to detect three compartments via capillary depletion, rather than just the standard two, has revealed important characteristics of capillary binding (Pan et al., 1997) . In the case of GM-CSF, however, we found that perfusion had no significant effect on the percentage of GM-CSF found in the capillaries.
The means by which GM-CSF crosses the blood-brain barrier was investigated with very high concentrations of unlabelled GM-CSF to inhibit the transport of the tracer amounts (fM/ml) of [ 125 I]GM-CSF used to detect passage. Self-inhibition of GM-CSF passage into the CNS demonstrates that passage is not mediated just by leakage or simple transmembrane diffusion, but rather is facilitated by a selective transport system. This may suggest the existence of a distinct GM-CSF transporter, but it is also possible that GM-CSF shares a transport system with some other substance(s), such as interleukin-4 or macrophage colonystimulating factor, substances with which GM-CSF shares a similar short chain fold (Rozwarski et al., 1994) , or with interleukin-3 and interleukin-5, whose receptors have a common chain with GM-CSF (Goodall et al., 1993) .
Serum GM-CSF concentrations are normally in the pg/ml range, but can fluctuate dramatically during infection, injury, chemotherapy or pregnancy (Omori et al., 1992; Imakawa et al., 1993) . GM-CSF has also been administered clinically in order to stimulate haematopoiesis in patients with low blood counts. In these cases doses are generally in the 10 µg/kg range, although some studies have used higher or lower concentrations (Hill et al., 1995) . In all these instances, however, blood concentrations are below the range of GM-CSF that would be needed to saturate the putative transporter.
Whether other serum factors, or pathological changes, might interfere with the putative GM-CSF transporter, remains to be seen. Unless such interference does occur, however, it may be presumed that the putative GM-CSF transporter would facilitate the entry of serum GM-CSF into brain under physiological conditions. GM-CSF is produced by several different tissues outside the CNS, including endocrine organs such as ovary, testis and placenta (Robertson and Seamark, 1992) . Blood-borne GM-CSF arriving in the CNS might have several consequences. GM-CSF receptors have been seen on oligodendrocytes and microglia (Baldwin et al., 1993) . The action of GM-CSF upon these receptors has been implicated in the formation of glial scars during epilepsy (Giulian et al., 1994) as well as in the response of glia to injury or infection (Raivich et al., 1993) .
Serum GM-CSF concentrations generally increase in response to infection, but in late-stage AIDS the serum concentrations of the cytokine decrease (Hober et al., 1993) . This response generally has been regarded as maladaptive, and has been treated clinically by the administration of exogenous GM-CSF (Capetti et al., 1995) . HIV-1 expression in the CNS, however, can be enhanced by GM-CSF (Benveniste, 1994) . Since GM-CSF crosses the blood-brain barrier, it is conceivable that the decrease in serum concentration may be the body's attempt to combat the propagation of HIV in the CNS.
In addition to neuroimmune and neuroregenerative actions, an additional role for GM-CSF has been implied by the recent findings that GM-CSF influences the release of melatonin (Zylinska et al., 1995) and LHRH (luteinizing hormone releasing hormone) (Kimura et al., 1996) , allowing for the possibility that GM-CSF has neuroendocrine functions. Indirect means of CNS entry, such as secretion from macrophages during injury or infection, might not provide for regular endocrine access to the CNS, but a blood-to-CNS transport system would be ideally suited to such a purpose. The high degree of variability observed in blood-brain barrier permeability to GM-CSF in female animals also suggests the possibility that circulating hormones could help regulate passage of GM-CSF into the brain.
In conclusion, the ability of GM-CSF to cross the bloodbrain and blood-spinal cord barriers may allow serum-borne GM-CSF to act directly on the CNS.
